Engineering T Cells to Functionally Cure HIV-1 Infection

Slides:



Advertisements
Similar presentations
Future directions in HIV basic science research The hunt for a cure.
Advertisements

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,
Control of Th2-Mediated Inflammation by Regulatory T Cells
Socializing Individualized T-Cell Cancer Immunotherapy
Volume 20, Issue 2, (February 2012)
Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Genome-editing Technologies for Gene and Cell Therapy
HIV-1 Latency by Transition
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
Volume 24, Issue 11, Pages (November 2016)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
The Influenza Virus Enigma
RNA Interference in Mammals: The Virus Strikes Back
RNA Interference in Mammals: The Virus Strikes Back
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Recent Developments in Retroviral-Mediated Gene Transduction
William J. Blake, James J. Collins  Cell 
Evolving Gene Therapy in Primary Immunodeficiency
Escaping the Valley of Death
Volume 26, Issue 2, Pages (February 2018)
Interleukin-17 Kick-Starts T Helper 1 Cell Differentiation
Volume 25, Issue 1, Pages 5-7 (January 2017)
The Other Face of Chimeric Antigen Receptors
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Genome-editing Technologies for Gene and Cell Therapy
Nicholas D Weber, Daniel Stone, Keith R Jerome  Molecular Therapy 
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
The Bare Lymphocyte Syndrome: Molecular Clues to the Transcriptional Regulation of Major Histocompatibility Complex Class II Genes  Angela DeSandro, Uma.
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
Innate Immune Sensing of HIV-1 by Dendritic Cells
Richard A Voit, Moira A McMahon, Sara L Sawyer, Matthew H Porteus 
Adenovirus Virion Stability and the Viral Genome: Size Matters
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
HIV-1 Vif: Counteracting Innate Antiretroviral Defenses
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
Antiviral Immunity and Circular RNA: No End in Sight
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
IL-7 Knocks the Socs Off Chronic Viral Infection
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
The Role of Human Dendritic Cells in HIV-1 Infection
Greg J. Towers, Mahdad Noursadeghi  Cell Host & Microbe 
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
Shigeki Yagyu, Malcolm K. Brenner
History of Oncolytic Viruses: Genesis to Genetic Engineering
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Morton J Cowan, Hans-Peter Kiem  Molecular Therapy 
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease
Recent Developments in Retroviral-Mediated Gene Transduction
Marking Emerging β- and γδ-Selected T Cells
Vincent Calvez, Marc Grandadam  Clinical Microbiology and Infection 
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Engineering T Cells to Functionally Cure HIV-1 Infection Rachel S Leibman, James L Riley  Molecular Therapy  Volume 23, Issue 7, Pages 1149-1159 (July 2015) DOI: 10.1038/mt.2015.70 Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Summary of gene-engineering and gene-editing strategies to functionally cure HIV-1 infection. A variety of antiviral proteins and antiviral RNAs have been intracellularly expressed in CD4 T cells to interfere with virus propagation early or late in the virus lifecycle, upon entry or in the nuclear or cytoplasmic stages of virus replication and virion assembly. Designer nucleases have been employed to disrupt expression of integrated proviruses and to generate HIV-resistant cells by knocking out the coreceptors required for virus entry. CD8 and CD4 T cells can be redirected to kill infected cells with HIV-specific TCRs and CARs. Immune-mediated control over HIV in the absence of HAART will likely require the protection of key CD4 T-cell helper subsets from HIV infection so that HIV-specific activation will result in effector functions including IL-2 and IL-21 production and expression of CD40 ligand. Molecular Therapy 2015 23, 1149-1159DOI: (10.1038/mt.2015.70) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions